FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1954244899> ?p ?o ?g. }

• W1954244899 endingPage "57" @default.
• W1954244899 startingPage "51" @default.
• W1954244899 abstract "To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.This is a phase III, randomised, double-blind, parallel-group, multicentre study with a 24-week primary endpoint. Patients with moderate to severe RA despite MTX treatment were randomised to receive weekly dose of 50 mg of subcutaneous SB4 or ETN. The primary endpoint was the American College of Rheumatology 20% (ACR20) response at week 24. Other efficacy endpoints as well as safety, immunogenicity and pharmacokinetic parameters were also measured.596 patients were randomised to either SB4 (N=299) or ETN (N=297). The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN. The 95% CI of the adjusted treatment difference was -9.41% to 4.98%, which is completely contained within the predefined equivalence margin of -15% to 15%, indicating therapeutic equivalence between SB4 and ETN. Other efficacy endpoints and pharmacokinetic endpoints were comparable. The incidence of treatment-emergent adverse events was comparable (55.2% vs 58.2%), and the incidence of antidrug antibody development up to week 24 was lower in SB4 compared with ETN (0.7% vs 13.1%).SB4 was shown to be equivalent with ETN in terms of efficacy at week 24. SB4 was well tolerated with a lower immunogenicity profile. The safety profile of SB4 was comparable with that of ETN.NCT01895309, EudraCT 2012-005026-30." @default.
• W1954244899 created "2016-06-24" @default.
• W1954244899 creator A5016628419 @default.
• W1954244899 creator A5018678002 @default.
• W1954244899 creator A5023193751 @default.
• W1954244899 creator A5034996501 @default.
• W1954244899 creator A5041653844 @default.
• W1954244899 creator A5041778235 @default.
• W1954244899 creator A5046036100 @default.
• W1954244899 creator A5048017786 @default.
• W1954244899 creator A5051107294 @default.
• W1954244899 creator A5054896185 @default.
• W1954244899 creator A5079921904 @default.
• W1954244899 creator A5082702151 @default.
• W1954244899 creator A5089382889 @default.
• W1954244899 date "2015-07-06" @default.
• W1954244899 modified "2023-10-09" @default.
• W1954244899 title "A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy" @default.
• W1954244899 cites W1487880507 @default.
• W1954244899 cites W1995228104 @default.
• W1954244899 cites W2008138329 @default.
• W1954244899 cites W2017376056 @default.
• W1954244899 cites W2019832147 @default.
• W1954244899 cites W2048049691 @default.
• W1954244899 cites W2054504654 @default.
• W1954244899 cites W2068338283 @default.
• W1954244899 cites W2071095038 @default.
• W1954244899 cites W2091732273 @default.
• W1954244899 cites W2097997129 @default.
• W1954244899 cites W2098767548 @default.
• W1954244899 cites W2111153776 @default.
• W1954244899 cites W2115200931 @default.
• W1954244899 cites W2116843833 @default.
• W1954244899 cites W2117623512 @default.
• W1954244899 cites W2128918690 @default.
• W1954244899 cites W2136731562 @default.
• W1954244899 cites W2146223797 @default.
• W1954244899 cites W2153919578 @default.
• W1954244899 cites W2169856473 @default.
• W1954244899 cites W2187675918 @default.
• W1954244899 cites W2314052274 @default.
• W1954244899 cites W2321723431 @default.
• W1954244899 cites W2340084730 @default.
• W1954244899 cites W2411192786 @default.
• W1954244899 doi "https://doi.org/10.1136/annrheumdis-2015-207588" @default.
• W1954244899 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5264222" @default.
• W1954244899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26150601" @default.
• W1954244899 hasPublicationYear "2015" @default.
• W1954244899 type Work @default.
• W1954244899 sameAs 1954244899 @default.
• W1954244899 citedByCount "186" @default.
• W1954244899 countsByYear W19542448992015 @default.
• W1954244899 countsByYear W19542448992016 @default.
• W1954244899 countsByYear W19542448992017 @default.
• W1954244899 countsByYear W19542448992018 @default.
• W1954244899 countsByYear W19542448992019 @default.
• W1954244899 countsByYear W19542448992020 @default.
• W1954244899 countsByYear W19542448992021 @default.
• W1954244899 countsByYear W19542448992022 @default.
• W1954244899 countsByYear W19542448992023 @default.
• W1954244899 crossrefType "journal-article" @default.
• W1954244899 hasAuthorship W1954244899A5016628419 @default.
• W1954244899 hasAuthorship W1954244899A5018678002 @default.
• W1954244899 hasAuthorship W1954244899A5023193751 @default.
• W1954244899 hasAuthorship W1954244899A5034996501 @default.
• W1954244899 hasAuthorship W1954244899A5041653844 @default.
• W1954244899 hasAuthorship W1954244899A5041778235 @default.
• W1954244899 hasAuthorship W1954244899A5046036100 @default.
• W1954244899 hasAuthorship W1954244899A5048017786 @default.
• W1954244899 hasAuthorship W1954244899A5051107294 @default.
• W1954244899 hasAuthorship W1954244899A5054896185 @default.
• W1954244899 hasAuthorship W1954244899A5079921904 @default.
• W1954244899 hasAuthorship W1954244899A5082702151 @default.
• W1954244899 hasAuthorship W1954244899A5089382889 @default.
• W1954244899 hasBestOaLocation W19542448991 @default.
• W1954244899 hasConcept C112705442 @default.
• W1954244899 hasConcept C126322002 @default.
• W1954244899 hasConcept C197934379 @default.
• W1954244899 hasConcept C198451711 @default.
• W1954244899 hasConcept C203092338 @default.
• W1954244899 hasConcept C2777226972 @default.
• W1954244899 hasConcept C2777575956 @default.
• W1954244899 hasConcept C2781059491 @default.
• W1954244899 hasConcept C535046627 @default.
• W1954244899 hasConcept C71924100 @default.
• W1954244899 hasConceptScore W1954244899C112705442 @default.
• W1954244899 hasConceptScore W1954244899C126322002 @default.
• W1954244899 hasConceptScore W1954244899C197934379 @default.
• W1954244899 hasConceptScore W1954244899C198451711 @default.
• W1954244899 hasConceptScore W1954244899C203092338 @default.
• W1954244899 hasConceptScore W1954244899C2777226972 @default.
• W1954244899 hasConceptScore W1954244899C2777575956 @default.
• W1954244899 hasConceptScore W1954244899C2781059491 @default.
• W1954244899 hasConceptScore W1954244899C535046627 @default.
• W1954244899 hasConceptScore W1954244899C71924100 @default.
• W1954244899 hasIssue "1" @default.
• W1954244899 hasLocation W19542448991 @default.
• W1954244899 hasLocation W19542448992 @default.

• next